Comparison of the efficacy of montelukast or ketotifen combined with salmeterol/fluticasone in the treatment of cough variant asthma
10.3760/cma.j.issn.1008-6706.2019.11.018
- VernacularTitle: 孟鲁司特与酮替芬联合沙美特罗/氟替卡松治疗咳嗽变异性哮喘的效果比较
- Author:
Yan YAO
1
;
Lijun WU
;
Jie YAN
Author Information
1. Department of Respiration, the 903rd Hospital of People's Liberation Army Joint Service Support Unit, Hangzhou, Zhejiang 310013, China
- Publication Type:Journal Article
- Keywords:
Asthma;
Cough;
Montelukast;
Ketotifen;
Salmeterol;
Flixonase;
Asthma;
Treatment outcome;
Recurrence
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(11):1357-1359
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of montelukast or ketotifen combined with salmeterol/fluticasone powder inhalation in the treatment of cough variant asthma.
Methods:From July 2016 to July 2017, 74 patients with cough-variant asthma admitted to the 903rd Hospital of People's Liberation Army Joint Service Support Unit were selected.According to the random number table method, the patients were randomly divided into the control group and observation group, with 37 patients in each group.All patients were treated with inhalation of salmeterol/fluticasone, with montelukast chewable tablets in the observation group, and ketotifen tablets in the control group.The adverse reactions in the two groups after treatment were recorded, and the treatment effect and typical asthma conversion rate in the two groups were compared.
Results:The total effective rate of the observation group was 94.59%, which was significantly higher than 78.38% of the control group (χ2=8.283, P<0.05). The incidence rate of adverse reactions was 10.81% in the observation group and 16.22% in the control group, there was no statistically significant difference between the two groups (χ2=2.082, P>0.05). In the observation group, 2 patients had nausea, and 2 patients had laryngopharyngeal discomfort.In the control group, 1 patient had laryngopharyngeal discomfort, 2 patients had dizziness, and 3 patients had somnolence.All the above symptoms were mild and could be relieved after symptomatic treatment.After 1 year of follow-up, the recurrence rate of the observation group was 27.03%, which was significantly lower than 43.24% of the control group (χ2=8.072, P<0.05). After 1 year of follow-up, the typical asthma conversion rate of the observation group was 21.62%, which was significantly lower than 37.84% of the control group (χ2=7.322, P<0.05).
Conclusion:Montelukast in the treatment of cough variant asthma can greatly reduce the recurrence rate and the conversion rate of typical asthma.It is not only safe but also effective.It is worthy of popularizing in clinic.
